Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Intraepidermal nerve fiber densitiy in non-diabetic with and without antecedents of DM2 in comparision with diabetic patients at the center of Mexico
General Neurology
P15 - Poster Session 15 (12:00 PM-1:00 PM)
6-005

Evaluate the difference of the intraepidermal nerve fiber density between non-diabetic subjects with and without antecedents of DM  in comparison with diabetic subjects in Mexico
Diabetic neuropathy (DN) is present in 10-15% of the patients recently diagnosed with DM2 and 50% of them will present it in 10 years. DN can produce positive (tingling, burning, stabbing pain and other abnormal sensations) and negative (sensory loss, weakness, and numbness) symptoms that interferes with daily life activities, make them feel psychosocially disabled and causes low quality of life. Nowadays the 128 Hz tuning fork to detect vibration or 10-g monofilament are the most used methods by the clinician to diagnose ND but they could yield subjective interpretation by the patient. The skin biopsy is emerging as a minimally invasive procedure that allows morphometric quantification of intraepidermal nerve fibers (IENF) expressed by section length as IENF/mm. The reference value for healthy subjects according to 2010 guidelines range from 9.8 + 3.6 to 13.8 + 6.7 fibers / mm.
Three groups of 7 subjects between 18-65 years were studied: controls, familial antecedents, and diabetics. A skin biopsy was done with a 3 mm punch, 100 mm above the malleolus. Using bright-field immunohistochemistry, PGP 9.5+ IENF were counted.

The mean age for each group was 36.8, 37.5 and 42.6 years for controls, familial antecedents and diabetics respectively. The mean value of IENF/mm was 9.9, 8.05 and 7.32 for each group. The OR for DN was 1 for healthy control, 6.2 for familial antecedents and 15 for diabetic subjects. The Kruskal-Wallis  showed a p-value of 0.075.

This is an ongoing trial that is recruiting patients yet, we show our partial results. The results evidence that subjects with familial antecedents have a higher risk to develop neuropathy. 
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Ildefonso Rodriguez-Leyva, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Facultad de Medicina, Universidad Autonoma de San Luis Potosi) Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Laboratorios Columbia.